熱門資訊> 正文
法雷奥制药报告第三季度业绩
2024-09-13 04:52
- Valeo Pharma press release (OTCQB:VPHIF): Q3 revenues of $12.6 million, down 11% from Q3-23, excluding XIIDRA, growth trend from continued business remains healthy at +9%, Q3-24 vs Q3-23
- Q3-24 adjusted EBITDA loss of $1.5 million compared to $2.5 million for Q3-23, down 40%.
- Enerzair and Atectura prescribing physicians reached, 4285 at the end of Q3-24, a 71% increase year-over-year.
- Total Enerzair and Atectura prescriptions for the 12 months ending July 31, 2024, exceeded 97,000, up 74% over the 12 months ending July 31, 2023.
More on Valeo Pharma
- Valeo Pharma appoints senior executive and Board of Director change
- Historical earnings data for Valeo Pharma
- Financial information for Valeo Pharma
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
